No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer
The majority of men treated for prostate cancer will eventually develop castrate-resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy, and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual’s information needs at all stages of disease are assessed and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately, we conclude that there is still a lack of good-quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms, and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required.
KeywordsMetastatic castrate resistant prostate cancer Information needs Decision making Treatment
We thank pH Associates for the administrative support and Sanofi for funding this scoping exercise.
Compliance with ethical standards
Conflict of interest
Dr. Jenkins and Professor Fallowfield’s group received funding from Ph Associates and Sanofi UK to conduct a scoping exercise in the area of mCRPC. The funders had no role in the research, literature review, or writing of this manuscript.
- 16.Ellis LM, Bernstein DS, Voest EE, et al. (2014) American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. 32(12):1277–1280Google Scholar
- 17.Cherny NI, Sullivan R, Dafni U, et al. (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26(8):1547–1573CrossRefPubMedGoogle Scholar